Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Rating of "Buy" from Brokerages

Key Points

• Aura Biosciences, Inc. has received an average consensus rating of "Buy" from nine brokerages, with a 1-year price target of $22.00.
• Insider trading activity included SVP Amy Elazzouzi selling 7,722 shares at an average price of $6.70, reducing her ownership by 8.19%.
• Institutional investors and hedge funds hold 96.75% of Aura Biosciences' stock, highlighting strong institutional interest in the company.

Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) has been given a consensus rating of "Buy" by the nine ratings firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $22.00.

AURA has been the topic of a number of recent analyst reports. HC Wainwright reissued a "buy" rating and issued a $22.00 price objective on shares of Aura Biosciences in a research note on Wednesday, August 13th. JMP Securities reissued a "market outperform" rating and issued a $19.00 price objective on shares of Aura Biosciences in a research note on Friday, May 23rd. Finally, Zacks Research raised Aura Biosciences from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 19th.

Insider Buying and Selling

In other Aura Biosciences news, SVP Amy Elazzouzi sold 7,722 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $6.70, for a total value of $51,737.40. Following the completion of the sale, the senior vice president owned 86,558 shares of the company's stock, valued at approximately $579,938.60. This trade represents a 8.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 6.30% of the company's stock.

Institutional Investors Weigh In On Aura Biosciences

A number of hedge funds have recently added to or reduced their stakes in AURA. Dimensional Fund Advisors LP grew its stake in Aura Biosciences by 25.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 365,824 shares of the company's stock valued at $3,007,000 after acquiring an additional 73,062 shares during the period. Northern Trust Corp grew its stake in Aura Biosciences by 6.3% in the fourth quarter. Northern Trust Corp now owns 387,269 shares of the company's stock valued at $3,183,000 after acquiring an additional 23,006 shares during the period. BNP Paribas Financial Markets acquired a new stake in Aura Biosciences in the fourth quarter valued at approximately $50,000. Bank of America Corp DE grew its stake in Aura Biosciences by 20.5% in the fourth quarter. Bank of America Corp DE now owns 51,286 shares of the company's stock valued at $422,000 after acquiring an additional 8,709 shares during the period. Finally, Deutsche Bank AG grew its stake in Aura Biosciences by 56.7% in the fourth quarter. Deutsche Bank AG now owns 44,085 shares of the company's stock valued at $362,000 after acquiring an additional 15,951 shares during the period. Institutional investors and hedge funds own 96.75% of the company's stock.

Aura Biosciences Price Performance

Shares of NASDAQ:AURA opened at $6.48 on Monday. The company has a market capitalization of $402.54 million, a price-to-earnings ratio of -3.31 and a beta of 0.45. The business's 50-day moving average is $6.64 and its 200-day moving average is $6.36. Aura Biosciences has a 1 year low of $4.34 and a 1 year high of $12.38.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. Analysts anticipate that Aura Biosciences will post -1.66 EPS for the current year.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.